FundaMental scientists have discovered a breakthrough molecular mechanism that allows to safely counteract glutamate excitotoxicity by specifically targeting the interface between NMDA and TRPM4 receptors (Yan, J., et al., Science, 2020). As such our small molecule Twin F interface inhibitors constitute an entirely new class of drugs that safely block glutamate excitotoxicity, a common cause of neurodegeneration and clinically validated mechanism. While FundaMental’s current focus is on Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), the applicability of these molecules extends to a range of neurogenerative disorders such as Alzheimer’s disease (AD) and aging-related memory loss.

Recent Milestones: Company raised to date EUR 13 M Seed financing which supports the ongoing medicinal chemistry lead optimization campaign to clinical candidate selection and corporate buildup.

Upcoming Milestones: i) orally bioactive and CNS penetrant Twin F interface inhibitors with low nanomolar potencies in organoids and primary neurons; ii) PoC in relevant disease model(s) with orally bioavailable and CNS penetrant Twin F interface inhibitor(s)

Investors: BioGeneration Ventures (www.biogenerationventures.com), Thuja Capital (www.thujacapital.com), Novartis Venture Fund (www.nvfund.com), High Tech Gründerfonds (www.htgf.de), coparion (www.coparion.vc)

Full Company address: FundaMental Pharma GmbH, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany Contact details: Dr. Thomas Schulze CEO FundaMental Pharma GmbH Cell: + 49 (0) 1717860209 E-Mail: Thomas.Schulze@fundamentalpharma.com